ArticleIn vivo (Athens, Greece)
Impact of PI-RADS During Active Surveillance for Prostate Cancer on Pathological Findings at Repeat Biopsy.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimThis study aimed to determine whether lesion visibility on magnetic resonance imaging (MRI) predicts rebiopsy outcomes during active surveillance for prostate cancer. PATIENTS AND
methodsWe retrospectively analyzed data from 111 patients enrolled in the Prostate Cancer Research International Active Surveillance study (Japan) at Kagawa University (January 2010-February 2025). After excluding 19 patients who discontinued active surveillance within one year, 92 patients were included in the analysis. MRI findings were classified as visible [Prostate Imaging Reporting and Data System (PI-RADS) score ≥3] or invisible (score ≤2). We assessed the association between visibility and rebiopsy outcomes, defined as reclassification progression beyond active surveillance criteria or no cancer.
resultsMRI was performed at diagnosis in 32.6% (n=32) of patients, at one year in 37.0% (n=34), and at four years in 47.7% (n=21). Lesion visibility at diagnosis was not associated with continuation of active surveillance compared with invisibility [median 43 months, 95% confidence interval (12-not available)
conclusionAt one year, a PI-RADS score ≥3 was associated with a higher risk of reclassification, whereas a score ≤2 was associated with a greater likelihood of no cancer on rebiopsy. These findings highlight the prognostic value of MRI in guiding active surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.